Encompass Health Co. (NYSE:EHC – Get Rating) saw a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 2,780,000 shares, a growth of 13.5% from the October 31st total of 2,450,000 shares. Based on an average daily trading volume, of 754,900 shares, the days-to-cover ratio is presently 3.7 days. Currently, 2.9% of the shares of the stock are short sold.

Analysts Set New Price Targets

Several analysts have issued reports on EHC shares. Truist Financial reduced their price target on shares of Encompass Health from $75.00 to $65.00 and set a "buy" rating on the stock in a report on Monday, August 8th. Raymond James upped their price target on shares of Encompass Health from $65.00 to $72.00 and gave the company a "strong-buy" rating in a report on Friday, October 28th. Royal Bank of Canada reduced their price target on shares of Encompass Health from $82.00 to $66.00 in a report on Wednesday, August 24th. StockNews.com started coverage on shares of Encompass Health in a report on Wednesday, October 12th. They issued a "hold" rating on the stock. Finally, Stephens reduced their price target on shares of Encompass Health from $60.00 to $58.00 and set an "overweight" rating on the stock in a report on Friday, October 28th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Encompass Health has a consensus rating of "Buy" and an average price target of $64.13.

Encompass Health Trading Up 0.4 %

Shares of EHC traded up $0.23 on Friday, hitting $57.99. 445,689 shares of the stock traded hands, compared to its average volume of 569,174. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 1.59. The firm has a market capitalization of $5.79 billion, a P/E ratio of 21.32, a P/E/G ratio of 2.82 and a beta of 1.06. The stock's 50 day moving average is $52.26 and its two-hundred day moving average is $53.16. Encompass Health has a 1 year low of $44.33 and a 1 year high of $74.61.

Encompass Health Announces Dividend

Insiders Place Their Bets

In related news, Director Greg D. Carmichael bought 1,830 shares of the stock in a transaction on Monday, October 31st. The shares were bought at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the transaction, the director now owns 10,546 shares of the company's stock, valued at approximately $576,549.82. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Encompass Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Mackenzie Financial Corp acquired a new position in Encompass Health during the second quarter worth approximately $289,000. Mitsubishi UFJ Trust & Banking Corp increased its position in Encompass Health by 12.4% during the second quarter. Mitsubishi UFJ Trust & Banking Corp now owns 8,996 shares of the company's stock worth $504,000 after purchasing an additional 995 shares during the last quarter. Hightower 6M Holding LLC acquired a new position in Encompass Health during the first quarter worth approximately $245,000. 1492 Capital Management LLC acquired a new position in Encompass Health during the second quarter worth approximately $221,000. Finally, Paradice Investment Management LLC acquired a new position in Encompass Health during the first quarter worth approximately $47,388,000. Institutional investors and hedge funds own 93.07% of the company's stock.

Encompass Health Company Profile

(Get Rating)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

See Also

• Get a free copy of the StockNews.com research report on Encompass Health (EHC)
• Why CSL Ltd Stock Could Be Worth a Look
• MarketBeat: Week in Review 11/28 – 12/02
• Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
• Institutions Are Buying Ambarella, Should You?
• Can ZIM Defy Broad Downturn In The Container Shipping Industry?

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.